Beijing Gene Key Life Technology Co., Ltd
Clinical trials sponsored by Beijing Gene Key Life Technology Co., Ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Immune cell therapy takes on untreatable liver cancer Results expected Nov 2026 (estimated)
- Can a new injection boost chemotherapy against pancreatic cancer? Results expected Mar 2027 (estimated)
- Immune cell infusion aims to free ARDS patients from ventilators Results expected Jul 2027 (estimated)
-
Immune cell infusion aims to free ARDS patients from ventilators
Disease control Not yet recruitingThis study tests an experimental therapy called GKL-006RTU, made from a type of immune cell (iNKT cells), for people with moderate to severe acute respiratory distress syndrome (ARDS), a life-threatening lung condition. The trial has two parts: first, a small group receives the c…
Phase 1/2 • Sponsor: Beijing Gene Key Life Technology Co., Ltd • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage trial tests an experimental therapy called GKL-006Allo, made from donor immune cells (iNKT cells), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the therapy's safety and how the body processes it.…
Phase 1 • Sponsor: Beijing Gene Key Life Technology Co., Ltd • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC